bioRxivMolecular BiologyPreprint
Intrinsic RNA targeting constrains the utility of CRISPR-Cas13 systems
Zexu LiiD, Zihan LiiD, Xiaolong ChengiD, Xiaofeng WangiD, Shixin MaiD, Shengnan WangiD, Zhiyan LuiD, Han ZhangiD, Wenchang ZhaoiD, Zhisong CheniD, Yingjia Yao, Lumen ChaoiD, Wei LiiD, Fei TengiD
- Citations
- 2
Abstract
CRISPR-Cas13 systems have been adapted as versatile toolkits for RNA-related applications. Here we systematically evaluate the performance of several popular Cas13 family effectors (Cas13a, Cas13b and Cas13d) under lentiviral vectors and reveal surprisingly differential defects and characteristics of these systems. Using RNA immunoprecipitation sequencing, transcriptome profiling, biochemistry analysis, high-throughput CRISPR-Cas13 screening and machine learning approaches, we determine that each Cas13 system has its intrinsic RNA targets in mammalian cells. Viral process-related host genes can be targeted by Cas13 and affect production of fertile lentiviral particles, thereby restricting the utility of lentiviral Cas13 systems. Multiple RNase activities of Cas13 are involved in endogenous RNA targeting. Unlike target-induced nonspecific collateral effect, intrinsic RNA cleavage can be specific, target-independent and dynamically tuned by varied states of Cas13 nucleases. Our work provides guidance on appropriate use of lentiviral Cas13 systems and further raises cautions about intrinsic RNA targeting during Cas13-based basic and therapeutic applications.
- organism: human
- assay: CRISPR screen
- research focus: benchmarking
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cytosolic CRISPR RNA for RNA-targeting CRISPR-Cas systems
Ezra C.K. Cheng, Jodie Lam, S. Chul Kwon·EMBO ReportsPeer-reviewed·Feb 26, 2025
- CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells
Yuxi Ai, Dongming Liang, Jeremy E. Wilusz·Nucleic Acids ResearchPeer-reviewed·Feb 21, 2022
- High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effect
Huawei Tong, Jia Huang, … Hui Yang·Nature BiotechnologyPeer-reviewed·Aug 11, 2022
- Enhanced RNA-targeting CRISPR-Cas technology in zebrafish
Ismael Moreno-Sánchez, Luis Hernández-Huertas, … Miguel A. Moreno-Mateos·Nature CommunicationsPeer-reviewed·Mar 16, 2025
- Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens
Xinyi Guo, Jahan A. Rahman, … Neville E. Sanjana·Cell GenomicsPeer-reviewed·Sep 3, 2021
- Efficient inhibition of HIV using CRISPR/Cas13d nuclease system
Hoang Nguyen, Hannah Wilson, … Smita Kulkarni·VirusesPeer-reviewed·Sep 16, 2021